One of the studies found that both human and mouse CRC tissue had considerably higher ILC2 levels than paracancerous tissue; in a mouse model, ILC2-derived IL-9 could activate CD8+ T cells to inhibit CRC tumor growth and using anti-CD90.2 to block ILC2s in nude mouse (lacking T cells) could promote tumor growth, whereas intravenously injecting IL-9 inhibited tumor growth (74). This evidence concerns the gene IL9 and neoplasm.